-The Indian Express West Bengal is not new to chit fund scams. What is unique to the Saradha Group scandal is how it targeted the poorest and the most marginalised, leaving them on the verge of devastation. From 17-year-old agents who raised money from depositors to 50-year-old widows who invested money, the Saradha Group didn't discriminate in roping them in. Since the house of cards started collapsing, two agents and two...

-Economic and Political Weekly While the Supreme Court decision in the recent Novartis case has cleared the way for production of generic drugs in India, doctors have to prescribe cheaper alternatives to costly brands if patients with limited means are to benefit. What is being hailed as a victory in the struggle for affordable medicines in the country will actually be one only when there is a pro-patient slant to the...

-The Hindu Business Line   The Bill does not take into account the extremely varied nature of land markets. It looks like the Land Acquisition, Rehabilitation And Resettlement Bill is going to be finally presented in Parliament for passage in the current session. The full details of what is in the current Bill aren't known because over 150 amendments may have been made to the last version that was available for public scrutiny. But...

-Down to Earth Inadequate sewage treatment and disposal in the national capital territory is contaminating city's groundwater Delhi residents who depend on groundwater for their drinking water needs be warned. The latest data of the Central Ground Water Board (CGWB) shows that groundwater samples taken from observation wells in the national capital are getting contaminated because of their unhygienic catchments and untreated sewage, which is discharged in the open and into drains,...

-The Times of India JAIPUR: In a major relief for blood cancer patients, the state's health department is all set to provide Imatinib tablets ("magic bullet" tablets) free of cost to them. The government's decision follows the April 1 Supreme Court decision to dismiss Swiss drug maker Novartis AG's attempt to win patent protection for its cancer drug Glivec (Imatinib). Currently the tablet is sold in the market by Novartis at...